Theremia
AI-driven platform to design drug derivatives with improved efficacy across diverse demographics.

AI-driven platform to design drug derivatives with improved efficacy across diverse demographics. For blockbuster drugs about to expire, Theremia’s solution is pharma companies’ only chance to protect their revenue.
Founders
Iris Maréchal
CEO
Iris is a former BCG consultant who has worked with some of the world’s leading pharma companies. As a student, she founded a nonprofit to national scale.

Chloé Geoffroy
CTO
Chloé is a Pharmacist and Chemical Engineer with a PhD and post-doc from École Normale Supérieure in Neuropharmacology.
Milestones
2024
Founded at Entrepreneur First
Seed (€3 million) led by Eurazeo and Salica Investment